This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Review

. 1990:53:83-100.

The efficacy of levodopa treatment declines in the course of Parkinson's disease: do nondopaminergic lesions play a role?

Y Agid¹, A M Graybiel, M Ruberg, E Hirsch, J Blin, B Dubois, F Javoy-Agid

Affiliations

PMID: 1978522

Review

The efficacy of levodopa treatment declines in the course of Parkinson's disease: do nondopaminergic lesions play a role?

Y Agid et al. Adv Neurol. 1990.

. 1990:53:83-100.

Authors

Y Agid¹, A M Graybiel, M Ruberg, E Hirsch, J Blin, B Dubois, F Javoy-Agid

Affiliation

¹ INSERM U 289, Hôpital de la Salpêtrière, Paris, France.

PMID: 1978522

No abstract available

PubMed Disclaimer

Similar articles

Interactions of exogenous L-dopa with nigrostriatal dopaminergic neurons in Parkinson's disease.
Melamed E. Melamed E. Adv Neurol. 1990;53:61-6. Adv Neurol. 1990. PMID: 2173376 Review. No abstract available.
Three types of akinesia in the progressive course of Parkinson's disease.
Narabayashi H. Narabayashi H. Adv Neurol. 1993;60:18-24. Adv Neurol. 1993. PMID: 8093577 Review. No abstract available.
[Dopamine agonists in the therapy of parkinson syndrome].
Kapfhammer HP, Rüther E. Kapfhammer HP, et al. Nervenarzt. 1985 Feb;56(2):69-81. Nervenarzt. 1985. PMID: 3982566 German. No abstract available.
Potential nondopaminergic drugs for Parkinson's disease.
Silverdale MA, Fox SH, Crossman AR, Brotchie JM. Silverdale MA, et al. Adv Neurol. 2003;91:273-91. Adv Neurol. 2003. PMID: 12442686 Review. No abstract available.
A review of some aspects of the pharmacology of levodopa.
Morris JG. Morris JG. Clin Exp Neurol. 1978;15:24-50. Clin Exp Neurol. 1978. PMID: 386308 Review.

See all similar articles

Cited by

Pharmacological treatment of Parkinson's disease: life beyond dopamine D2/D3 receptors?
Linazasoro G, Van Blercom N, Ugedo L, Ruiz Ortega JA. Linazasoro G, et al. J Neural Transm (Vienna). 2008;115(3):431-41. doi: 10.1007/s00702-007-0852-z. Epub 2008 Feb 4. J Neural Transm (Vienna). 2008. PMID: 18250954 Review.
Cerebral cortical areas in which thickness correlates with severity of motor deficits of Parkinson's disease.
Lyoo CH, Ryu YH, Lee MS. Lyoo CH, et al. J Neurol. 2011 Oct;258(10):1871-6. doi: 10.1007/s00415-011-6045-6. Epub 2011 Apr 22. J Neurol. 2011. PMID: 21512741
Characterization of Motor and Non-Motor Behavioral Alterations in the Dj-1 (PARK7) Knockout Rat.
Kyser TL, Dourson AJ, McGuire JL, Hemmerle AM, Williams MT, Seroogy KB. Kyser TL, et al. J Mol Neurosci. 2019 Oct;69(2):298-311. doi: 10.1007/s12031-019-01358-0. Epub 2019 Jun 27. J Mol Neurosci. 2019. PMID: 31250274
Role of dopamine in learning and memory: implications for the treatment of cognitive dysfunction in patients with Parkinson's disease.
Kulisevsky J. Kulisevsky J. Drugs Aging. 2000 May;16(5):365-79. doi: 10.2165/00002512-200016050-00006. Drugs Aging. 2000. PMID: 10917074 Review.
Levodopa effects on hand and speech movements in patients with Parkinson's disease: a FMRI study.
Maillet A, Krainik A, Debû B, Troprès I, Lagrange C, Thobois S, Pollak P, Pinto S. Maillet A, et al. PLoS One. 2012;7(10):e46541. doi: 10.1371/journal.pone.0046541. Epub 2012 Oct 9. PLoS One. 2012. PMID: 23056337 Free PMC article.

See all "Cited by" articles

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions

LinkOut - more resources

Other Literature Sources
- The Lens - Patent Citations Database
Medical
- MedlinePlus Health Information